Rheumatology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis
Rheumatology, 10/23/09

Derk CT et al. – In this prospective open-label study of mycophenolate mofetil for the treatment of dcSSc, we observed significant improvements in skin scores, peripheral vascular involvement and patient-perceived health status. Pulmonary function studies did not worsen as expected, but instead showed a trend towards improvement.

Methods

15 patients with dcSSc
Open-label study using mycophenolate mofetil to treat their disease over 12-month period
Primary outcome measure was modified Rodnan skin score (mRSS), whereas secondary outcomes included Medsger severity score, pulmonary function studies, 2D echocardiograms and Short Form Health Survey (SF)-36 questionnaire

Results

mRSS significantly improved in patients who tolerated medication for > 3 months , and there was a statistically significant improvement in the Medsger severity scores of the general , peripheral vascular involvement and skin scores
SF-36 scores improved and pulmonary function studies showed trend towards improvement, though not of statistical significance
No change in mean pulmonary artery pressure by 2D echocardiography

<< Previous
Doxycycline for osteoarthritis of the knee or hip

Next >>
Long-Term Effects of Pamidronate in Thalassemic Patients with...